The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
A potentially functional polymorphism in the promoter region of miR‐34b/c is associated with an increased risk for primary hepatocellular carcinoma
Abstract
The miR‐34 family members are direct transcriptional targets of tumor suppressor p53, and loss of miR‐34 function can impair p53‐mediated cell cycle arrest and apoptosis. A potentially functional SNP rs4938723 (T > C) was found in the promoter region of pri‐miR‐34b/c (423 bp from the transcription start site), located in the CpG island and might affect transcription factor GATA binding and therefore pri‐miR‐34b/c expression. In our study, we hypothesized that SNPs miR‐34b/c rs4938723 and TP53 Arg72Pro may independently or jointly contribute to primary hepatocellular carcinoma (HCC) susceptibility. We then genotyped the 2 SNPs in a case–control study of 501 patients with primary HCC and 548 cancer‐free controls in a Chinese population. We observed that the variant genotypes of miR‐34b/c rs4938723 were associated with significantly increased HCC risks compared with the wild‐type TT genotype (adjusted OR = 1.37, 95% CI =1.06–1.78 for TC; OR = 1.53, 95% CI = 1.02–2.31 for CC and OR = 1.40, 95% CI = 1.10–1.80 for TC/CC). Furthermore, we found a significant interaction between alcohol drinking and SNP rs4938723 on HCC risk (p = 0.05 for multiplicative and p = 0.01 for additive interaction). However, we did not find any main effect of TP53 Arg72Pro on HCC risk in this population. These findings indicate that the potentially functional SNP rs4938723 in the promoter region of pri‐miR‐34b/c may contribute to the susceptibility of HCC in this Chinese population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
A microRNA component of the p53 tumour suppressor network
He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., et al. (2007) · Nature · doi:10.1038/nature05939 · Cited by 2,692
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Chang, T.-C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C. J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.010 · Cited by 2,010
The miR-34 family in cancer and apoptosis
Hermeking, H. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.56 · Cited by 1,236
GATA transcription factors as potentiators of gut endoderm differentiation
Bossard, P., & Zaret, K. S. (1998) · Development · doi:10.1242/dev.125.24.4909 · Cited by 313
Cited by
Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches
Beermann, J., Piccoli, M.-T., Viereck, J., & Thum, T. (2016) · Physiological Reviews · doi:10.1152/physrev.00041.2015 · Cited by 1,726
Single nucleotide polymorphisms and cancer susceptibility
Deng, N., Zhou, H., Fan, H., & Yuan, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.22372 · Cited by 381
Semi-supervised learning for potential human microRNA-disease associations inference
Chen, X., & Yan, G.-Y. (2014) · Scientific Reports · doi:10.1038/srep05501 · Cited by 374
Clinical Applications for microRNAs in Cancer
Nana-Sinkam, S. P., & Croce, C. M. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.192 · Cited by 352
Noncoding RNA mutations in cancer
Zhou, H., Hao, X., Zhang, P., & He, S. (2023) · WIREs RNA · doi:10.1002/wrna.1812 · Cited by 24
Metadata
- Authors
- Xu, Y., Liu, L., Liu, J., Zhang, Y., Zhu, J., Chen, J., Liu, S., Liu, Z., Shi, H., Shen, H., & Hu, Z.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2010-11-23
- Volume
- 128
- Issue
- 2
- Pages
- 412-417
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2092516659
- Cited by
- 189
- References
- 5
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.